Tuesday, October 20, 2020

ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis

Cancer shared this article with you from Inoreader

41417_2020_245_Fig1_HTML.png

Cancer Gene Therapy, Published online: 17 October 2020; doi:10.1038/s41417-020-00245-w

ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis
View on the web

No comments:

Post a Comment

Collaboration request

Hi there How would you like to earn a 35% commission for each sale for life by selling SEO services Every website owner requires the ...